Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Swedish Orphan Biovitrum AB ( (SE:SOBI) ) has issued an announcement.
Swedish Orphan Biovitrum AB has convened its Annual General Meeting for 6 May 2026 in Stockholm, offering shareholders the choice of attending in person or voting by post. Shareholders must be registered with Euroclear Sweden by 27 April 2026 and confirm participation, with clear procedures laid out for those attending physically, voting by proxy or using postal voting.
The notice details administrative requirements including power-of-attorney rules, nominee-registered share re-registration and the deadline for postal votes. The proposed agenda covers standard AGM items such as approval of financial statements, reports from the CEO and board, and a resolution on profit or loss appropriation, underlining routine but important governance and shareholder-oversight processes.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK470.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (Sobi) is a Stockholm-based biopharmaceutical company focused on rare diseases. It develops and markets specialty medicines, primarily targeting hematology, immunology and other orphan indications for patients in Europe and globally.
Average Trading Volume: 455,491
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK132.1B
Learn more about SOBI stock on TipRanks’ Stock Analysis page.